Fred Hutchinson Cancer Institute develops nomogram to determine individualized estimates of screen-detected prostate cancer overdiagnosis
Fred Hutchinson Cancer Institute researchers have developed a nomogram that incorporates age, Gleason score, and prostate-specific antigen (PSA) level at diagnosis, so that an individual’s risk that a screen-detected prostate cancer has been overdiagnosed can be estimated, according to a new study published January 6 in the Journal of the National Cancer Institute. The authors used a standard definition of overdiagnosis to refer to a cancer that would not have become symptomatic or clinically identifiable if it had not been detected by screening.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.